Navigation Links
Ajinomoto Group Expands Cysteine Derivatives Production Capacity
Date:7/15/2014

Tokyo, Japan (PRWEB) July 15, 2014

Ajinomoto Co., Inc. (Ajinomoto Co.) has announced that its subsidiary Nippon Protein Co., Ltd. in Japan will increase Cysteine derivatives production capacity during 2014.

Cysteine derivatives are amino acids widely used in various applications such as pharmaceutical products, bread (dough conditioner), flavors and cosmetics. Many Cysteine derivatives from other manufacturers are produced through an extraction process using animal-origin material, such as human hair and bird feathers; however, Ajinomoto Co. has developed a production method by fermentation based on raw material from vegetable sources. Making use of our own technology for producing Cysteine derivatives, Ajinomoto Co. began supplying fermentation-origin products to the market last year.

The demand for fermentation-origin Cysteine derivatives is dramatically increasing as the demand for animal-source products has fallen. Human hair and bird feather extraction methods are losing favor, in part due to the heavy environmental burdens - such as the creation of large amounts of waste water - that result from the process. Accordingly, demand for our fermentation-origin Cysteine derivatives - which is considered sustainable - is surging globally. Ajinomoto Co. is expanding to accommodate this increased demand and will prepare for further expansion to cope with customers’ demand.

Ajinomoto will make the best effort to meet the market requirement by making use of our advantageous fermentation technology.

Read the full story at http://www.prweb.com/releases/Ajinomoto-Expands-/Cysteine-Derivatives/prweb12012952.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Page: 1

Related biology technology :

1. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
2. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference
3. BioNeutral Group Receives $400,000 in Equity Financing
4. MiMedx Group Completes $5,000,000 Private Placement
5. Use Biomarkers in Alzheimers Disease Clinical Trials, Says Expert Group
6. MiMedx Group, Inc. Receives CE Certification for Its CollaFix™ Surgical Mesh CD
7. Lend Lease Announces the Appointment of Tom Chapman as Director Operations for the Life Sciences Group in the Atlantic Region
8. Statewide Network of Angel Investor Groups Announced in Alabama
9. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2011 Financial Results on Wednesday, March 7, 2012
10. Weikang Bio-Technology Group Co., Inc. Is Expected to Achieve the Net Profit of at Least $26 Million
11. MiMedx Group Announces 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... WEST LAFAYETTE, Indiana (PRWEB) , ... ... ... a division of Albany Molecular Research Inc. has further extended its industry ... sector. This service offers state-of-the-art cGMP techniques and methods for the ...
(Date:2/15/2017)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial ... full year ended December 31, 2016. ... we continued to demonstrate strong growth in our ... said Mihael H. Polymeropoulos, M.D., Vanda,s President and ... 2017 milestones underscores Vanda,s commitment to bringing important ...
Breaking Biology Technology:
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
Breaking Biology News(10 mins):